Search - tctmd.com

Displaying 1 - 20 of 104

Sort: Relevancy | Date

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Conference News CRT 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Yael L. Maxwell

February 27, 2023

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Features

Expired Cardiac Devices May Do Global Good, but Safety Unknown

Yael L. Maxwell

August 26, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

Shelley Wood

October 30, 2020

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

News Features

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Yael L. Maxwell

November 27, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Michael O'Riordan

January 08, 2019

Advertisement

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Expired Cardiac Devices May Do Global Good, but Safety Unknown

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

TCTMD’s Top 10 Most Popular Stories for October 2020

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content